AzTrials
AzTrials

Low Back Pain, MechanicalPhase 3NCT02521519

Short Terms Effects of Medial Branch Block vs Para-spinal Muscle Injection in Patients With Non-specific CLBP

A Phase 3 study testing Medial branch block in one side and paravertebral deep intramuscular (PDI) injection in people with Low Back Pain, Mechanical, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study compares the efficacy of medial branch block (MBB) vs. paravertebral deep intramuscular (PDI) injection for pain relief in chronic low back pain. Based on randomization in first intervention session, one side receives MBB and the other side takes PDI and in second session the pattern reverses. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Low Back Pain, Mechanical
What is being tested?
Medial branch block in one side and paravertebral deep intramuscular (PDI) injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteCanada
Study dates
25 Aug 2014to 27 Jan 2020
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • CLBP of non-malignant origin fulfilling the following criteria:
  • Pain lasting for at least three months
  • Pain in both the left and right sides of the back
  • Pain below the L2 vertebral body
  • Lumbar spine CT scan or MRI done in the last 2 years
  • Average visual analogue scale (VAS) for pain ≥4/10 on each side for the 3 days
  • Cognitive and physical ability to provide informed consent in English or French

Who cannot join

  • Neurologic signs or symptoms suggesting nerve root involvement
  • Strictly unilateral Low Back Pain (LBP)
  • CT scan or MRI findings suggestive of pain etiology beyond degenerative spine disease
  • Vascular malformations
  • Tumor
  • Infection
Show all 15Show fewer
  • Fractures
  • DISH (Diffuse idiopathic skeletal hyperostosis)
  • Patients who have received injections of any type or acupuncture therapy to the low back in the last 3 months
  • Prior spine surgery
  • Local or systemic infection
  • Bleeding disorder or the use of anticoagulation medications but for low-dose aspirin
  • Known allergy to amid local anesthetics
  • Active insurance claim (CSST, SAAQ)
  • Uncontrolled psychiatric condition

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Alan Edwards Pain Management Unit - Montreal General Hospital

    Montreal, Quebec, H3G 1A4

Other trials in Canada

About this study

Official title: Short Term Effects of Medial Branch Block vs Para-spinal Injection in Muscle Patients With Non-specific Chronic Low Back Pain

This study compares the efficacy of medial branch block (MBB) vs. paravertebral deep intramuscular (PDI) injection for pain relief in chronic low back pain. Based on randomization in first intervention session, one side receives MBB and the other side takes PDI and in second session the pattern reverses.

Read the detailed description

Pain relief following medial branch block (MBB) might be due to facet joints desensitization and/or myofascial trigger points' desensitization. Patients will be randomized to two groups. The first group receives MBB in one side and paravertebral deep intramuscular (PDI) injection in the other side of the back. Next week the pattern of injection will be reversed so the side which had received MBB will take PDI injection and PDI side will take MBB. Second group takes the intervention in reverse order.

Being tested
Medial branch block in one side, paravertebral deep intramuscular (PDI) injection
Keywords
Facet induced pain, Myofascial pain, Trigger points, Low back pain
Medical subject headings
Low Back Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Medial branch block in one sideOther

    MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.

  • paravertebral deep intramuscular (PDI) injectionOther

    injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.

Study groups in NCT02521519
Study groupRoleWhat they receive
One side of the patient's backOthermedial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
Receives: Other: Medial branch block in one side
Other side of the patient's backOtherThese injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
Receives: Other: paravertebral deep intramuscular (PDI) injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Chronic Low Back Pain (CLBP) measured by VAS

    Measured: Seven days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2015 (estimated)
  2. Study start25 Aug 2014
  3. Primary completion22 Jan 2019
  4. Study completion27 Jan 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02521519
Sponsor's protocol ID
14-190
Status last verified
Oct 2026
First submitted
7 Aug 2015
Last updated
26 Oct 2026
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Medial branch block in one side and paravertebral deep intramuscular (PDI) injection in people with Low Back Pain, Mechanical, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early. Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Chronic Low Back Pain (CLBP) measured by VAS (time frame: Seven days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in